Group 1 - The core viewpoint of the article indicates that Xiangsheng Medical is set to release its 2025 annual report, with a reported net profit of 116.6 million yuan, reflecting a year-on-year decrease of 16.99% [1] Group 2 - During the reporting period, the company achieved an operating revenue of 447.35 million yuan, a decrease of 4.55% compared to the same period last year [2] - The net profit attributable to the parent company was 116.63 million yuan, down 16.99% year-on-year, while the net profit after deducting non-recurring gains and losses was 103.36 million yuan, a decline of 18.69% [2] - Basic earnings per share were reported at 1.04 yuan, a decrease of 17.46% compared to the previous year [2] - At the end of the reporting period, the company had total assets of 1.598 billion yuan, an increase of 0.11% year-on-year, while the equity attributable to the parent company decreased by 2.59% to 1.384 billion yuan [2] - The decline in net profit was primarily attributed to a decrease in operating revenue and foreign exchange losses due to fluctuations in the US dollar exchange rate [2] Group 3 - Xiangsheng Medical specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment, providing various ultrasound medical imaging devices and professional technical development services to domestic and international medical institutions and research organizations [4] - In the last 90 days, three institutions have given buy ratings for the stock [5]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Xiangsheng Medical (688358), indicating a slight increase in stock price and a mixed financial outlook for the company [1][2]. Group 2 - As of February 25, 2026, Xiangsheng Medical's stock closed at 34.57 yuan, with a 0.93% increase, a turnover rate of 1.09%, a trading volume of 12,200 shares, and a transaction amount of 41.99 million yuan [1]. - On February 25, the net inflow of main funds was 2.57 million yuan, accounting for 6.13% of the total transaction amount, while retail investors experienced a net outflow of 0.12 million yuan, representing 0.29% of the total [1]. - For the first three quarters of 2025, the company reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.92 million yuan, down 4.56% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, a decline of 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [2]. - The company has a debt ratio of 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan, while maintaining a gross profit margin of 59.82% [2]. - Xiangsheng Medical specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, providing various ultrasound medical imaging devices and professional technical development services to domestic and international medical institutions and research organizations [2]. Group 3 - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical, indicating positive sentiment among analysts [3].

Core Viewpoint - Xiangsheng Medical (688358) has shown a mixed financial performance with a decline in revenue and net profit for the first three quarters of 2025, while the third quarter showed a significant increase in net profit compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [1] - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 86.97 million yuan, a decrease of 2.69% year-on-year [1] - In Q3 2025, the single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [1] - The single-quarter net profit attributable to shareholders was 24.22 million yuan, an increase of 41.95% year-on-year [1] - The single-quarter net profit after deducting non-recurring gains and losses was 23.14 million yuan, an increase of 53.63% year-on-year [1] - The company's debt ratio stands at 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [1] - The gross profit margin is reported at 59.82% [1] Market Activity - As of February 9, 2026, the stock closed at 35.76 yuan, with a slight increase of 0.14% [1] - The turnover rate was 1.45%, with a trading volume of 16,300 hands and a transaction amount of 58.01 million yuan [1] - On February 9, the net outflow of main funds was 4.99 million yuan, accounting for 8.6% of the total transaction amount, while retail funds saw a net inflow of 1.02 million yuan, accounting for 1.75% [1] Analyst Ratings - In the last 90 days, three institutions have given buy ratings for the stock [2]

Core Viewpoint - Xiangsheng Medical (688358) has experienced a decline in stock price and financial performance, with a focus on its ultrasound medical imaging equipment business [1] Financial Performance - As of February 5, 2026, Xiangsheng Medical's stock closed at 35.6 yuan, down 0.95%, with a trading volume of 9,475 lots and a transaction amount of 33.89 million yuan [1] - For the first three quarters of 2025, the company reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.92 million yuan, down 4.56% [1] - In Q3 2025, the company recorded a single-quarter main revenue of 107 million yuan, a year-on-year decrease of 6.68%, while the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [1] - The company's gross profit margin stands at 59.82%, with a debt ratio of 11.24% [1] Investment Ratings - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical [2]

Core Viewpoint - Xiangsheng Medical (688358) has shown a mixed financial performance with a decline in revenue and net profit for the first three quarters of 2025, while the third quarter showed a significant increase in net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [2]. - The net profit attributable to the parent company was 93.92 million yuan, down 4.56% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 86.97 million yuan, a decrease of 2.69% year-on-year [2]. - In the third quarter of 2025, the company's single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [2]. - The single-quarter net profit attributable to the parent company was 24.22 million yuan, an increase of 41.95% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 23.14 million yuan, an increase of 53.63% year-on-year [2]. - The company's debt ratio was 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [2]. - The gross profit margin stood at 59.82% [2]. Stock Performance - As of February 3, 2026, Xiangsheng Medical's stock closed at 36.17 yuan, up 3.64% with a turnover rate of 1.32% and a trading volume of 14,800 hands, amounting to a transaction value of 53.04 million yuan [1]. - On February 3, the net outflow of main funds was 191,700 yuan, accounting for 0.36% of the total transaction value, while the net outflow of speculative funds was 5.54 million yuan, accounting for 10.44% of the total transaction value [1]. - Retail investors saw a net inflow of 5.73 million yuan, representing 10.8% of the total transaction value [1]. Analyst Ratings - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical [3].

Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price and revenue, indicating potential challenges in the company's financial performance and market position [1]. Financial Performance - As of February 2, 2026, Xiangsheng Medical's stock closed at 34.9 yuan, down 4.7%, with a trading volume of 17,900 hands and a transaction value of 63.8582 million yuan [1]. - For the first three quarters of 2025, the company reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.9205 million yuan, down 4.56% [1]. - The third quarter of 2025 showed a single-quarter main revenue of 107 million yuan, a year-on-year decrease of 6.68%, while the net profit attributable to shareholders increased by 41.95% to 24.2241 million yuan [1]. - The company’s gross profit margin stands at 59.82%, with a debt ratio of 11.24% and investment income of 3.0123 million yuan [1]. Market Activity - On February 2, 2026, the net outflow of main funds was 823.24 thousand yuan, accounting for 12.89% of the total transaction value, while retail investors saw a net inflow of 229.04 thousand yuan, representing 3.59% of the total transaction value [1]. - Over the last 90 days, three institutions have given buy ratings for the stock, indicating a positive outlook from analysts [2].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Xiangsheng Medical (688358), indicating a slight increase in stock price and mixed financial results for the third quarter of 2025 [1][2]. Group 2 - As of January 30, 2026, Xiangsheng Medical's stock closed at 36.62 yuan, with a 0.33% increase, a turnover rate of 1.09%, and a trading volume of 12,200 hands, resulting in a transaction amount of 44.32 million yuan [1]. - In terms of capital flow on January 30, 2026, the net outflow of main funds was 597,900 yuan, accounting for 1.35% of the total transaction amount, while retail investors saw a net inflow of 2.84 million yuan, representing 6.41% of the total transaction amount [1]. Group 3 - For the first three quarters of 2025, Xiangsheng Medical reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.92 million yuan, down 4.56% year-on-year [2]. - The third quarter of 2025 showed a single-quarter main revenue of 107 million yuan, down 6.68% year-on-year, but a net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [2]. - The company has a debt ratio of 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan, while maintaining a gross profit margin of 59.82% [2]. Group 4 - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical, indicating positive sentiment among analysts [3].

Core Viewpoint - Xiangsheng Medical (688358) has shown a positive stock performance with a closing price of 38.64 yuan, up 5.54% as of January 21, 2026, indicating a favorable market sentiment towards the company [1]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the net profit excluding non-recurring items was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. - The gross profit margin stood at 59.82%, indicating a strong profitability despite the revenue decline [3]. Market Activity - On January 21, 2026, the net inflow of main funds was 12.60 million yuan, accounting for 8.9% of the total transaction amount, while retail investors experienced a net outflow of 15.15 million yuan, representing 10.71% of the total transaction amount [1]. - Over the past five days, the financing buy amounted to 16.43 million yuan, with a net repayment of 40,400 yuan, indicating a cautious approach from investors [2]. Institutional Ratings - In the last 90 days, three institutions have issued buy ratings for Xiangsheng Medical, reflecting a positive outlook from analysts [4].

Company Overview - Xiangsheng Medical Technology Co., Ltd. is located in Wuxi, Jiangsu Province, and was established on January 30, 1996. The company went public on December 3, 2019. Its main business involves the research, development, manufacturing, and sales of ultrasound medical imaging equipment [1]. - The revenue composition of the company is as follows: 91.12% from ultrasound medical imaging equipment, 6.49% from accessories and others, 2.27% from technical service fees, and 0.12% from other sources [1]. Stock Performance - As of the latest report, Xiangsheng Medical's stock price increased by 1% to 30.29 CNY per share, with a trading volume of 8.7364 million CNY and a turnover rate of 0.26%. The total market capitalization is 3.396 billion CNY [1]. Fund Holdings - The fund "Lobomai China Medical Health Stock Initiation A" (020142) holds a significant position in Xiangsheng Medical, with 47,000 shares, accounting for 6.76% of the fund's net value, making it the fourth-largest holding [2]. - The fund was established on December 26, 2023, with a latest scale of 16.336 million CNY. Year-to-date returns are 17.51%, ranking 2966 out of 4195 in its category, while the one-year return is 15.01%, ranking 3086 out of 4179 [2]. - The fund manager, Li Tao, has been in charge for 2 years and 6 days, with a total asset scale of 22.8582 million CNY. The best and worst fund returns during his tenure are -5.15% and -6.31%, respectively [2].

Core Viewpoint - Despite a decline in both revenue and net profit for 2024, Xiangsheng Medical (688358.SH) continues to face pressure in its performance for the first three quarters of this year, yet has decided to implement a cash dividend to stabilize investor confidence [1][2]. Financial Performance - For the first three quarters of this year, Xiangsheng Medical reported revenue of approximately 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 105 million yuan, down 2.23% [2][3]. - The company's revenue for 2024 was 469 million yuan, reflecting a 3.13% decline, while the net profit decreased by 4.08% to 141 million yuan [2][3]. - The cash dividend proposed is 3 yuan per 10 shares, amounting to a total of 33.56 million yuan, which represents 35.73% of the net profit for the period [2]. Accounts Receivable - As of the end of the third quarter of 2025, Xiangsheng Medical's accounts receivable reached 198 million yuan, an increase of 22% from the previous year, indicating growing pressure on cash flow [3]. Project Delays - Two key fundraising projects, "Research and Innovation and Marketing Operations Base Construction" and "Innovation and Development Reserve Fund," have been postponed to the end of 2026 due to uncontrollable construction factors and quality control needs [1][5]. - The delay in these projects may hinder the company's research and market positioning, impacting its long-term competitiveness [1][5][7]. Market Sentiment - The decision to maintain cash dividends amidst declining performance aims to bolster investor confidence, although previous announcements of significant shareholder reductions have affected market sentiment [3][4].